Full Text View
Tabular View
No Study Results Posted
Related Studies
Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
This study is ongoing, but not recruiting participants.
Study NCT00075868   Information provided by National Cancer Institute (NCI)
First Received: January 9, 2004   Last Updated: May 9, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Anal Cancer
Colorectal Cancer
Drug/Agent Toxicity by Tissue/Organ
Radiation Enteritis
Additional conditions recognized in this trial
Anus Neoplasms
Colorectal Neoplasms
Crohn Disease
Enteritis
Ileitis
Rectal Neoplasms
More general conditions related to this trial
Anus Diseases
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastroenteritis
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Ileal Diseases
Inflammatory Bowel Diseases
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases
Interventions listed in this trial
octreotide acetate
Additional drug interventions recognized in this trial
Octreotide
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Gastrointestinal Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Radiation Therapy Oncology Group
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services